查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080391

癌症疫苗市場：2026-2032年全球市場預測（依產品類型、劑型、給藥途徑、治療策略、疾病分期、適應症及最終用戶分類）

Cancer Vaccines Market by Product Type, Formulations, Route Of Administration, Treatment Strategy, Disease Stage, Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症疫苗市場規模將達到 212.8 億美元，複合年成長率為 10.66%。

主要市場統計數據
基準年 2025 104.6億美元
預計年份：2026年 115.5億美元
預測年份 2032 212.8億美元
複合年成長率 (%) 10.66%

癌症疫苗執行摘要

癌症疫苗正從免疫腫瘤學領域的一個小眾概念轉變為癌症預防和治療的戰略支柱。這一類別包括已證實有效的預防性疫苗，例如人類乳突病毒（HPV）疫苗和乙型肝炎疫苗，以及旨在利用新抗原、胜肽、樹突狀細胞、病毒載體或mRNA激活腫瘤特異性免疫反應的治療平台。

癌症疫苗領域的變革性變化

精準腫瘤學、快速定序以及聯合治療免疫療法的臨床檢驗正在重塑癌症疫苗的模式。研發重點正從標準化的腫瘤相關抗原（TAA）策略轉向針對每位患者腫瘤突變和HLA譜型量身定做的個人化新抗原疫苗。

人工智慧（AI）的累積影響

人工智慧（AI）正在為整個癌症疫苗價值鏈帶來累積優勢。 AI模型正被擴大用於預測新抗原的免疫抗原性、評估HLA結合、分析多組體學資料集、識別患者亞群以及最佳化臨床試驗的患者招募。這些能力縮短了藥物發現的時間，並提高了所選抗原誘導具有臨床意義的免疫反應的機率。

關於癌症疫苗的關鍵區域性見解

北美憑藉其強大的腫瘤學研究網路、美國國家癌症研究所 (NCI) 支持的計畫、美國食品藥物管理局監管方面的經驗以及良好的創業融資環境，仍然是癌症疫苗創新領域的領先地區。美國和加拿大也受益於基因組檢測的高普及率、完善的臨床試驗基礎設施以及免疫查核點抑制劑的廣泛應用，這些都為癌症治療性疫苗的聯合治療創造了有利環境。歐洲的優勢包括成熟的癌症中心、歐洲藥品管理局 (EMA) 的監管、歐洲地平線計劃 (Horizo​​​​n Europe) 的研究資助以及對先進療法生產日益成長的興趣；然而，定價、報銷和醫療技術評估要求會影響歐盟、英國和其他歐洲市場對相關療法的接受度。

該組織在主要經濟區的主要觀點

在東協地區，癌症疫苗的商業機會與人類乳突病毒(HPV)疫苗的推廣、區域臨床試驗的參與、癌症篩檢力度的加大以及新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國對生物製藥生產日益成長的興趣密切相關。海灣合作理事會（GCC）成員國大力投資精準醫療、國家級基因組學、電子健康記錄和專業癌症中心，這使得該地區具備了有選擇地推出融合先進免疫腫瘤技術和伴隨診斷的癌症疫苗計畫的優勢。

來自重點癌症疫苗市場主要國家的見解

美國在癌症疫苗臨床試驗、創業融資、FDA先例以及產學研合作方面發揮著主導作用，而加拿大則擁有強大的腫瘤學研究能力、豐富的人群健康資料集以及利用真實世界數據（RWE）的能力。墨西哥和巴西為參與拉丁美洲重要的臨床試驗提供了途徑，並在預防感染疾病相關癌症（尤其是子宮頸癌和肝癌）方面具有重要的公共衛生意義。英國、德國、法國、義大利和西班牙擁有先進的癌症中心、基因組醫學計畫和成熟的監管流程，儘管保險報銷審查日益嚴格。另一方面，俄羅斯雖然積極進行科學研究，但受到地緣政治因素以及資金籌措的影響。

為行業領導者提供的實用建議

產業領導者應優先考慮那些能夠展現明確生物學證據、可重複的免疫活化以及與聯合治療相容性的平台。計畫設計應圍繞檢驗的生物標記、可靠的伴隨診斷以及能夠支持監管審查、臨床效用評估和保險公司批准的患者選擇策略。

調查方法

本執行摘要基於三角驗證的二手研究和行業分析，使用了來自權威資訊來源的公開信息，例如世界衛生組織、國際癌症研究機構、美國食品藥品監督管理局、歐洲藥品管理局、ClinicalTrials.gov、同行檢驗的腫瘤學日誌、已發布的監管文件和領先的癌症研究組織。

結論

隨著腫瘤治療朝著早期療育、個人化免疫療法和持續免疫控制的方向發展，癌症疫苗正進入一個更具商業性價值的階段。雖然疫苗接種已證實能有效降低癌症發生率，但治療性疫苗的研發管線正透過mRNA平台、新抗原科學、病毒載體、樹突細胞療法和人工智慧驅動的抗原篩選等技術而變得日益複雜。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癌症疫苗市場：依產品類型分類

  • 預防性癌症疫苗
  • 用於治療的癌症疫苗

第8章：癌症疫苗市場：以劑型分類

  • 細胞衍生疫苗
    • 樹突細胞疫苗
    • 癌細胞疫苗
  • 核酸疫苗
    • DNA疫苗
    • RNA疫苗
  • 基於胜肽和蛋白質的疫苗
  • 合成疫苗
  • 病毒載體疫苗

第9章：癌症疫苗市場：依給藥途徑分類

  • 皮內給藥
  • 皮下
  • 肌肉內部
  • 靜脈

第10章 癌症疫苗市場：依治療策略分類

  • 單藥治療
  • 聯合治療

第11章：癌症疫苗市場：依疾病階段分類

  • 早期
  • 局部進展
  • 轉移性
  • 復發或再發

第12章：癌症疫苗市場：依適應症分類

  • 固體癌
    • 攝護腺癌
    • 子宮頸癌
    • 肺癌
    • 黑色素瘤
    • 乳癌
    • 結腸癌
    • 卵巢癌
    • 膀胱癌
    • 頭頸癌
  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤

第13章：癌症疫苗市場：依最終用戶分類

  • 癌症研究機構
  • 醫院和診所
  • 專業癌症治療中心

第14章 癌症疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：癌症疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 癌症疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Merck & Co., Inc.
  • GSK PLC
  • Dynavax Technologies Corporation
  • Serum Institute of India Pvt. Ltd.
  • Dendreon Pharmaceuticals LLC
  • JW CreaGene
  • Amgen Inc.
  • AstraZeneca PLC
  • BioNTech SE
  • Bristol Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CureVac SE
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring BV
  • Helsinn Healthcare SA
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc
  • Moderna, Inc.
  • OS Therapies
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA0514B

The Cancer Vaccines Market is projected to grow by USD 21.28 billion at a CAGR of 10.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.46 billion
Estimated Year [2026] USD 11.55 billion
Forecast Year [2032] USD 21.28 billion
CAGR (%) 10.66%

Cancer Vaccines Executive Summary

Cancer vaccines are moving from a niche immuno-oncology concept to a strategic pillar of cancer prevention and treatment. The category includes proven preventive vaccines, such as human papillomavirus and hepatitis B vaccines, as well as therapeutic platforms designed to activate tumor-specific immune responses using neoantigens, peptides, dendritic cells, viral vectors, or mRNA.

The need is substantial: the International Agency for Research on Cancer estimated 20.0 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with more than 35 million new cases projected by 2050. This burden is accelerating investment in cancer vaccine development, combination immunotherapy, biomarker-led clinical trials, and scalable manufacturing models.

Transformative Shifts in the Cancer Vaccine Landscape

The cancer vaccines landscape is being reshaped by precision oncology, rapid sequencing, and the clinical validation of immunotherapy combinations. Development priorities are shifting from standardized tumor-associated antigen approaches toward personalized neoantigen vaccines tailored to each patient's tumor mutations and HLA profile.

At the same time, mRNA vaccine infrastructure built during the COVID-19 era has improved confidence in rapid design, production, and clinical deployment. Market participants are also prioritizing checkpoint inhibitor combinations, earlier-line treatment settings, and measurable residual disease strategies to improve response durability and demonstrate health-economic value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative advantage across the cancer vaccine value chain. AI models are increasingly used to predict neoantigen immunogenicity, evaluate HLA binding, analyze multi-omics datasets, identify patient subgroups, and optimize trial enrollment. These capabilities can shorten discovery timelines and improve the probability that selected antigens generate clinically meaningful immune responses.

AI is also strengthening manufacturing analytics, quality control, pharmacovigilance, and real-world evidence generation. However, industry leaders must pair AI-enabled speed with validated datasets, transparent model governance, regulatory documentation, and clinically interpretable outputs to support FDA, EMA, and other agency expectations.

Key Regional Insights for Cancer Vaccines

North America remains a leading region for cancer vaccine innovation due to deep oncology research networks, NCI-supported programs, FDA experience with immunotherapy regulation, and strong venture funding. The United States and Canada also benefit from high use of genomic testing, established clinical trial infrastructure, and broad adoption of immune checkpoint inhibitors, creating a favorable environment for therapeutic cancer vaccine combinations. Europe benefits from established cancer centers, EMA oversight, Horizon Europe research funding, and growing interest in advanced therapy manufacturing, although pricing, reimbursement, and health technology assessment requirements influence adoption across the European Union, the United Kingdom, and other European markets.

Asia-Pacific is expanding through China's clinical trial scale, Japan's regenerative medicine frameworks, South Korea's biologics capabilities, Australia's oncology trial ecosystem, and India's vaccine manufacturing base. The region also has major relevance for preventive cancer vaccines because WHO and national immunization programs continue to emphasize HPV vaccination for cervical cancer prevention and hepatitis B vaccination for liver cancer prevention. Latin America, the Middle East, and Africa present rising long-term demand driven by cervical, liver, and other infection-associated cancers. In Latin America, public immunization programs and oncology trial participation support access pathways, while the Middle East is investing in precision medicine, national genomics, and specialist cancer centers. Africa has a high need for preventive vaccination and early cancer detection, but access, cold-chain capacity, reimbursement, oncology workforce availability, and genomic infrastructure remain decisive constraints.

Key Group Insights Across Major Economic Blocs

Within ASEAN, cancer vaccine opportunities are linked to HPV vaccination expansion, regional trial participation, rising cancer screening initiatives, and growing biologics manufacturing ambition in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is investing in precision medicine, national genomics, digital health records, and specialized cancer centers, positioning the group as a selective adopter of advanced immuno-oncology technologies and companion diagnostic-enabled cancer vaccine programs.

The European Union supports translational research, cross-border clinical development, regulatory standardization, and centralized evaluation of novel immunotherapies, while BRICS countries offer large patient populations, cost-efficient clinical development, and expanding biomanufacturing capacity across China, India, Brazil, Russia, and South Africa. G7 markets continue to shape reimbursement evidence, intellectual property standards, clinical trial quality, and regulatory expectations for personalized cancer vaccines. NATO member markets are also relevant through resilient supply chain planning, biosecurity priorities, cold-chain reliability, cross-border medical innovation networks, and coordinated preparedness for advanced biologics manufacturing.

Key Country Insights for Priority Cancer Vaccine Markets

The United States leads in cancer vaccine clinical trials, venture funding, FDA precedent, and academic-industry partnerships, while Canada contributes strong oncology research, population health datasets, and real-world evidence capabilities. Mexico and Brazil offer important Latin American trial access and public-health relevance for infection-related cancers, particularly cervical and liver cancer prevention. The United Kingdom, Germany, France, Italy, and Spain combine advanced cancer centers, genomic medicine programs, and mature regulatory pathways with evolving reimbursement scrutiny, while Russia remains scientifically active but affected by geopolitical, funding, and access constraints.

China is rapidly scaling domestic immuno-oncology pipelines, clinical trial enrollment, sequencing capacity, and biologics manufacturing. India combines high disease burden with large-scale vaccine manufacturing strength, expanding digital health infrastructure, and increasing oncology trial participation. Japan supports advanced therapies through mature regulation, strong translational science, and established oncology care pathways. Australia is a favored early-phase oncology trial hub due to efficient trial start-up processes, high-quality clinical sites, and diverse patient recruitment opportunities. South Korea is gaining visibility through biologics manufacturing, digital health infrastructure, national cancer screening experience, and precision oncology investment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that demonstrate clear biological rationale, reproducible immune activation, and compatibility with combination regimens. Programs should be designed around validated biomarkers, robust companion diagnostics, and patient-selection strategies that can support regulatory review, clinical utility assessment, and payer acceptance.

Commercial readiness requires investment in sequencing logistics, individualized manufacturing capacity, cold-chain control, decentralized clinical workflows, and quality systems aligned with advanced biologics requirements. Organizations should also pursue partnerships with cancer centers, genomic testing providers, CDMOs, clinical research networks, and public-health organizations to improve trial speed, manufacturing reliability, equitable access, and evidence generation across diverse populations.

Research Methodology

This executive summary is based on triangulated secondary research and industry analysis using publicly available information from authoritative sources, including the WHO, IARC, FDA, EMA, ClinicalTrials.gov, peer-reviewed oncology journals, public regulatory documents, and major cancer research organizations.

The methodology emphasizes verified epidemiology, regulatory precedent, clinical development activity, technology trends, preventive vaccination evidence, and regional healthcare infrastructure. Insights were assessed for relevance to cancer vaccine commercialization, therapeutic development, preventive vaccination, manufacturing scalability, reimbursement readiness, regulatory feasibility, and competitive positioning across mature and emerging markets.

Conclusion

Cancer vaccines are entering a more commercially relevant phase as oncology shifts toward earlier intervention, personalized immunotherapy, and durable immune control. Preventive vaccination already provides proven cancer-reduction value, while therapeutic vaccine pipelines are becoming more sophisticated through mRNA platforms, neoantigen science, viral vectors, dendritic cell approaches, and AI-enabled antigen selection.

The strongest opportunities will favor organizations that combine clinical rigor with manufacturing agility, regulatory discipline, data infrastructure, and access planning. As cancer incidence rises globally, cancer vaccines are positioned to become an increasingly important component of precision oncology and population-level cancer prevention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Vaccines Market, by Product Type

  • 7.1. Preventive Cancer Vaccines
  • 7.2. Therapeutic Cancer Vaccines

8. Cancer Vaccines Market, by Formulations

  • 8.1. Cell-Based Vaccines
    • 8.1.1. Dendritic Cell Vaccines
    • 8.1.2. Tumor Cell Vaccines
  • 8.2. Nucleic Acid-Based Vaccines
    • 8.2.1. DNA Vaccines
    • 8.2.2. RNA Vaccines
  • 8.3. Peptide/Protein-Based Vaccines
  • 8.4. Synthetic Vaccines
  • 8.5. Viral Vector-Based Vaccines

9. Cancer Vaccines Market, by Route Of Administration

  • 9.1. Intradermal
  • 9.2. Subcutaneous
  • 9.3. Intramuscular
  • 9.4. Intravenous

10. Cancer Vaccines Market, by Treatment Strategy

  • 10.1. Monotherapy
  • 10.2. Combination Therapy

11. Cancer Vaccines Market, by Disease Stage

  • 11.1. Early Stage
  • 11.2. Locally Advanced
  • 11.3. Metastatic
  • 11.4. Recurrent Or Relapsed

12. Cancer Vaccines Market, by Indication

  • 12.1. Solid Tumors
    • 12.1.1. Prostate Cancer
    • 12.1.2. Cervical Cancer
    • 12.1.3. Lung Cancer
    • 12.1.4. Melanoma
    • 12.1.5. Breast Cancer
    • 12.1.6. Colorectal Cancer
    • 12.1.7. Ovarian Cancer
    • 12.1.8. Bladder Cancer
    • 12.1.9. Head & Neck Cancer
  • 12.2. Hematologic Malignancies
    • 12.2.1. Leukemia
    • 12.2.2. Lymphoma
    • 12.2.3. Multiple Myeloma

13. Cancer Vaccines Market, by End-User

  • 13.1. Cancer Research Institutes
  • 13.2. Hospitals & Clinics
  • 13.3. Specialty Cancer Treatment Centers

14. Cancer Vaccines Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Cancer Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Merck & Co., Inc.
  • 18.2. GSK PLC
  • 18.3. Dynavax Technologies Corporation
  • 18.4. Serum Institute of India Pvt. Ltd.
  • 18.5. Dendreon Pharmaceuticals LLC
  • 18.6. JW CreaGene
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. BioNTech SE
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Celldex Therapeutics, Inc.
  • 18.12. CureVac SE
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. Ferring B.V.
  • 18.16. Helsinn Healthcare SA
  • 18.17. Inovio Pharmaceuticals, Inc.
  • 18.18. Johnson & Johnson Services, Inc
  • 18.19. Moderna, Inc.
  • 18.20. OS Therapies
  • 18.21. Pfizer Inc.
  • 18.22. Sanofi SA
  • 18.23. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREVENTIVE CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREVENTIVE CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREVENTIVE CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THERAPEUTIC CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THERAPEUTIC CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUMOR CELL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUMOR CELL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUMOR CELL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE/PROTEIN-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE/PROTEIN-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE/PROTEIN-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYNTHETIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYNTHETIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EARLY STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EARLY STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EARLY STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LOCALLY ADVANCED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LOCALLY ADVANCED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LOCALLY ADVANCED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL METASTATIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL METASTATIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL METASTATIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RECURRENT OR RELAPSED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RECURRENT OR RELAPSED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RECURRENT OR RELAPSED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CERVICAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CERVICAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CERVICAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLADDER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BLADDER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLADDER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HEAD & NECK CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEAD & NECK CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HEAD & NECK CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SPECIALTY CANCER TREATMENT CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SPECIALTY CANCER TREATMENT CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SPECIALTY CANCER TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 256. G7 CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 261. NATO CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 262. NATO CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 264. NATO CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 342. FRANCE CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. FRANCE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. FRANCE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 353. FRANCE CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 354. RUSSIA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 355. RUSSIA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. RUSSIA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 357. RUSSIA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 359. RUSSIA CANCER VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 360. RUSSIA CANCER VACCINES MARKET SIZE, BY TREATMENT STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 361. RUSSIA CANCER VACCINES MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 362. RUSSIA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 363. RUSSIA CANCER VACCINES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 364. RUSSIA CANCER VACCINES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 365. RUSSIA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 366. ITALY CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 367. ITALY CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 368. ITALY CANCER VACCINES MAR